Category: Pharmaceuticals
-
![Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms]()
Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.
-
![Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market]()
Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market
Currently in Canada, the dry eye market is estimated at over $9O million, which includes both prescription and over-the-counter products.
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
NeuPath Health Inc (NPTH.V): Where a little attention could go a long way
“In Canada, it’s not fundamentals, but sentiment that moves markets”…boy, if I had a nickel for everytime I heard that, I would have invested in Well Health Technologies (WELL.T) (nothing against $WELL!), and I would have been a couple of thousand dollars richer. If only there was a way to prove that. Allow me: It…
-
Aequus Pharmaceuticals (AQS.V) gets Health Canada device licence approval, validates business model
Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-platforming existing approved biotech and health products to appeal to a wider market, has announced another win Monday morning with news Health Canada has approved the advancing of their Evolve dry-eye relief gel line to an easy-squeeze eye drop bottle. Admittedly,…
-
Bio-tech without the dice roll: Aequus Pharmaceuticals (AQS.V) building a solid, multi-pronged revenue earner
For the last several years, a lot of stories I’ve written on this site have been about promise. The promise of something better, cheaper, with more upside, with less downside. Promise that a team will do more, or do better, or do something – anything. Promise that, if the planets align, something big will come.…
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
-
Valeo Pharma (VPH.c) and why you should care about bioflavonoids
Doing what we do at Equity Guru, every day, we receive emails and dms from shareholders of different companies – all expressing their grievances. Disgruntled with various issues such as failed management promises, lackluster progress, heavily diluted share structure, etc… As a result, it makes it even more satisfying to introduce our audience to companies…
-
Heritage Cannabis (CANN.C) acquires Opticann – to create an international medical footprint
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”.
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…
